SummaryThe inhibition of immediate allergen‐induced airflow obstruction by lodoxamide tromethamine (LT), a new drug with properties considered to be similar to those of sodium cromoglycate, was studied in twelve young asthmatic volunteers. Single aerosolized doses of 0.01 mg LT, 0.1 mg LT or placebo were administered by inhalation 15 min prior to allergen provocation at weekly intervals, in a double‐blind random order study. Following inhalation of both doses of LT a significantly greater amount of allergen had to be administered to cause a 20 fall in the forced expiratory volume in one second (FEV1) from control levels than was the case following placebo pre‐treatment (P<0.001). After single‐dose inhalation of LT only minor unwanted effects were recorded; in particular a transient feeling of heat in the upper respiratory tract after inhalation of the higher dose
展开▼
